

Article Title

Risk of Severe COVID–19 Outcomes Among Patients with Rheumatoid Arthritis in the United States

Corresponding Author

Full Name

Vincent Yau

Postal Address

Genentech
Building 40
600 E Grand Ave
South San Francisco, 94080
Email
yau.vincent@gene.com

Co-Authors

Full Name

Ching-Yi Chuo

Department
Institution
City
Country

Personalized Health Care
Genentech
South San Francisco
United States

Vince Yau

Department
Institution
City
Country

Personalized Health Care
Genentech
South San Francisco
United States

Sriraman Madhavan

Department
Institution
City
Country

Personalized Health Care
Genentech
South San Francisco
United States

Larry Tsai

Department
Institution
City
Country

Product Development
Genentech
South San Francisco
United States

Jenny Chia

Department
Institution
City
Country

Personalized Health Care
Genentech
South San Francisco
United States

Competing Interests: All authors on this paper are employed by Genentech, which is a member of the Roche Group.

Contributorship: All authors in this manuscript contributed in a meaningful and significant manner.

Acknowledgements: N/A

Funding Info: This study was funded by Genentech.

Ethical approval information:

The protocol for this study is in line with the Declaration of Helsinki (2008). The authors conducted secondary research using de-identified data licensed from TriNetX in compliance with 45 CFR 164.514(a)-(c). The data had identifying information removed and was coded in such a way that the data could not be linked back to subjects from whom it was originally collected.

This research utilized the data licensed by TriNetX and described above, does not require IRB or ethics review, as analyses with this data do not meet the definition of “research involving human subjects” as defined within 45 CFR 46.102(f) which stipulates human subjects as living individuals about whom an investigator obtains identifiable private information for research purposes. Neither the provider of the data nor the researchers were able to link the data with identifiable individuals. Consent to participate was not applicable in this retrospective observational study of de-identified data.

Data Sharing Statement: Data may be obtained from a third party and are not publicly available. This study used data provided by the TriNetX (Cambridge, MA) DataWorks network, which includes 41 Healthcare Organizations (HCOs) and 1,016,769 patients across the United States as of 20 August 2020. In order to use these data, Genentech purchased a license from TriNetX.

Patient and Public Involvement: We included the following statement in the main manuscript: “While this study used patient level data from a large electronic medical record database, no patients or members of the public contributed to the design or analysis of this study.”

Key Messages:

- Patients with Rheumatoid Arthritis (RA) tend to be older, and often have co-morbidities which could put them at greater risk of severe COVID-19 outcomes.
- This study is one of the largest studies of COVID-19 infected RA populations to date. We did not find increased risk of hospitalization, ICU admission, or mortality among RA patients vs. matched non-RA patients.
- Patients previously exposed to anti-coagulants experienced higher risks of hospitalization and overall mortality. Extra attention is needed for treating such patients.

Abstract

Introduction

Coronavirus disease 2019 (COVID–19) has infected over 22 million individuals worldwide. It remains unclear whether patients with COVID–19 and Rheumatoid Arthritis (RA) experience worse clinical outcomes compared to similar patients with COVID–19 without RA.

Aim

The aim of this study is to provide insights on how COVID-19 impacted patients with RA given the nature of the disease and medication used.

Methods

RA cases were identified via International Classification of Diseases (ICD) codes and COVID–19 cases by laboratory results in the U.S. based TriNetX network. Patients with COVID–19 and RA were propensity–score matched based on demographics with patients with COVID–19 without RA at a 1:3 ratio. A hospitalized sub-population was defined by procedure codes.

Results

We identified 1,014 COVID-19 patients with RA and 3,042 non-RA matches selected from 137,757 patients. The odds of hospitalization (non-RA:23%, RA:24.6%, OR:1.08, 95% CI: 0.88 to 1.33) or mortality (non-RA:5.4%, RA:6%, OR:0.93, 95% CI: 0.65 to 1.34) were not significantly different.

The hospitalized sub-population included 249 patients with COVID-19 and RA and 745 non-RA matches selected from 21,435 patients. The risk of intensive care unit (ICU) admission (non-RA:18.8%, RA:18.1%, OR:0.94, 95% CI: 0.60 to 1.45), and inpatient mortality (non-RA:14.4%, RA:14.5%, OR:0.86, 95% CI: 0.53 to 1.40) were not significantly different.

Conclusion

We didn't find evidence suggesting patients with COVID–19 and RA are more likely to have severe outcomes than patients with COVID–19 without RA.

Keywords

Rheumatoid Arthritis; COVID-19; hospitalization; mortality; intensive care unit.

Introduction

Coronavirus disease 2019 (COVID-19) has, as of 20 August 2020, infected over 222 million individuals worldwide and caused over 783,000 deaths.¹ Age is the most important risk factor for mortality.² Older individuals account for 80% of hospital admissions for COVID-19 infection and mortality risk among hospitalized individuals over 65 years old is 23 times greater than individuals under 65.³

Increased age is also associated with increased prevalence of comorbidities such as diabetes and hypertension which could contribute to worse outcomes in COVID-19 infected individuals.⁴ While several comorbidities such as obesity have been associated with worse outcomes,⁵ it is still unclear whether or not patients with COVID-19 and Rheumatoid Arthritis (RA) experience worse clinical outcomes compared to COVID-19 patients without RA. Patients with RA have higher risk of infections due to disease-related immune dysregulation and RA treatments which modulate patient immune responses.^{6,7} This has raised patient concerns about whether or not to continue RA treatments during the pandemic.⁸

Ironically, several RA medications, rather than being seen as risk factors, have been evaluated as COVID-19 treatments. Several immune modulating RA drugs like dexamethasone have seen widespread use around the world for COVID-19, and others are being evaluated such as interleukin6 (IL-6) inhibitors due to hypotheses that they might reduce risk of severe immune mediated COVID-19 outcomes.⁹

In this study, we compare the health outcomes COVID-19 positive patients with and without RA. This analysis will provide insight into how COVID-19 has affected this vulnerable population.

Methods

Data Source

The study used the TriNetX (Cambridge, MA) DataWorks network with 41 Healthcare Organizations (HCOs) and 1,016,769 patients across the United States. This COVID-19 specific dataset includes electronic medical records (diagnoses, procedures, medications, and laboratory values) primarily from large academic institutions with better representation of the south (41%, west (23%), midwest (15%) and northwest (17%)).

Study Population

Patients were required to have confirmed COVID-19 as defined by meeting one of three criteria: 1) Patients with at least one occurrence of International Classification of Diseases, 10th Revision, Clinical Modification (ICD10-CM) code U07.1 or 2) at least one occurrence of ICD10-CM code B97.29 without a negative COVID-19 laboratory test within 7 days or 3) positive antibody or RNA based COVID-19 laboratory test. The study period was between 20 February and 20 August 2020. Index date was defined as the first date fulfilling any of the above definitions.

Patients with COVID-19 were then classified as with RA or without RA. RA was defined as having at least two occurrences of ICD9-CM code 714.0 or corresponding ICD10-CM codes (online supplemental table S1) anytime in their medical records. We also collected information on all RA specific and other treatments such as Disease-Modifying Antirheumatic Drugs (DMARD) such as conventional synthetic (CS), targeted synthetic (TS), and Biologics ([B],

steroids, anti-coagulants and antibiotics; online supplemental table S2) taken within the year prior to index date. There are two main populations: 1) individuals who met our COVID-19 definitions and 2) a sub-population of hospitalized patients as defined by procedure codes (table S3).

Outcomes

The outcomes of interest for all COVID-19 patients were hospitalization and post COVID-19 mortality reported by the HCOs. For the hospitalized sub-population, the outcomes of interest were ICU admission and mortality (online supplemental table S3).

Statistical Analysis

For each patient-population, we conducted 1:3 propensity score matching using the nearest neighbor method with 0.1 caliper for age, gender, race, and smoking status on their RA status. Two-proportion-z-tests were used to compare the crude proportions of outcomes. Multiple logistic regressions controlling for matching variables, Charlson Comorbidity Index (CCI), Body Mass Index (BMI), and prior medication were used to derive outcome estimates. All analyses were conducted using R (3.5.1)

Sensitivity Analysis

Sensitivity analyses were conducted by restricting the COVID-19 definition to only lab confirmed cases.

Ethics

This study used de-identified patient level data from a large electronic medical record database that met Section 164.514 (a) of the HIPAA privacy rule and therefore not considered “research involving human subjects”.

Results

We identified 138,792 COVID-19 cases and among them, 1,035 were RA patients. Patients with RA and COVID-19 were older (without RA, with RA median age: 44, 63), more likely to be female (without RA, with RA: 55%, 79%), and non-Hispanic (see [Table 1](#)). RA patients were also more likely to be smokers (without RA, with RA: 6.5%, 24.5%), with slightly higher BMI and comorbidity burden. RA patients had higher prior-year medication utilization across all treatment classes. However, since the utilization of tsDMARDs was low (n=93), we did not separately assess tsDMARD use.

Comparing the pre-matched crude proportions of the outcomes between COVID-19 patients with RA and (n=1,035) and without RA (n=137,757), the former group had a significantly higher hospitalization rate (24.7% vs. 15.6%, $p < 0.05$) and mortality (6.3% vs. 2.5%, $p < 0.05$). Once hospitalized, the patients with and without RA had similar likelihoods of transferring to the ICU (with RA 18.0%, without RA 16.7%, $p = 0.64$) and inpatient mortality (with RA 14.8%, without RA 11.6%, $p = 0.13$).

Table 1 Demographics, Prior Medication Use and Selected Outcomes Comparison Between Patients with COVID-19 with Rheumatoid Arthritis and Patients with COVID-19 without Rheumatoid Arthritis

	Without RA pre-matched (n = 137,757)	Without RA matched (n=3,042)	With RA (n = 1,035)	All COVID-19 (n = 138,792)
Age				
Mean (SD)	45.0 (19.7)	61.5 (16.6)	61.8 (14.6)	45.2 (19.7)
Median [Q1, Q3]	44.0 [29.0, 60.0]	64.0 [51.0, 73.0]	63.0 [52.0, 72.0]	44.0 [30.0, 60.0]
Missing	1,897 (1.4%)		15 (1.4%)	1,912 (1.4%)
Sex				
Female	75,404 (54.7%)	2446 (80.4%)	816 (78.8%)	76,220 (54.9%)
Male	61,432 (44.6%)	596 (19.6%)	213 (20.6%)	61,645 (44.4%)
Unknown	921 (0.7%)		6 (0.6%)	927 (0.7%)
Race				
American Indian or Alaska Native	749 (0.5%)	17 (0.6%)	2 (0.2%)	751 (0.5%)
Asian	3,335 (2.4%)	44 (1.4%)	18 (1.7%)	3,353 (2.4%)
Black or African American	32,089 (23.3%)	871 (28.6%)	286 (27.6%)	32,375 (23.3%)
Native Hawaiian or Other Pacific Islander	306 (0.2%)	5 (0.2%)	0 (0%)	306 (0.2%)
White	68,925 (50.0%)	1508 (49.6%)	528 (51.0%)	69,453 (50.0%)
Unknown	32,353 (23.5%)	597 (19.6%)	201 (19.4%)	32,554 (23.5%)
Ethnicity				
Hispanic or Latino	25,079 (18.2%)	398 (13.1%)	124 (12.0%)	25,203 (18.2%)
Not Hispanic or Latino	61,425 (44.6%)	1537 (50.5%)	541 (52.3%)	61,966 (44.6%)
Unknown	51,253 (37.2%)	1107 (36.4%)	370 (35.7%)	51,623 (37.2%)
Smoking				
No	128,754 (93.5%)	2320 (76.3%)	781 (75.5%)	129,535 (93.3%)
Yes	9,003 (6.5%)	722 (23.7%)	254 (24.5%)	9257 (6.7%)
BMI (kg/m2)				
Mean (SD)	27.8 (5.94)	28.5 (5.93)	28.8 (6.02)	27.8 (5.94)
Median [Q1, Q3]	27.0 [23.0, 32.0]	28.0 [24.0, 33.0]	29.0 [25.0, 33.0]	27.0 [23.0, 32.0]
Missing	97,928 (71.1%)	2002 (65.8%)	490 (47.3%)	98,418 (70.9%)
CCI (weighted score based on				

comorbid conditions)				
Mean (SD)	0.660 (1.68)	1.39 (2.39)	3.07 (2.86)	0.678 (1.71)
Median [Q1, Q3]	0.00 [0.00, 0.00]	0 [0, 2.00]	2.00 [1.00, 4.50]	0.00 [0.00, 0.00]
bDMARD= biologics disease-modifying antirheumatic drugs; CCI= Charlson Comorbidity Index; COVID-19= Coronavirus disease 2019; csDMARD= conventional synthetic disease-modifying antirheumatic drugs; ICU= intensive care unit; RA= Rheumatoid Arthritis; SD= standard deviation; tsDMARD= targeted synthetic disease-modifying antirheumatic drugs; Q1= quartile 1; Q3= quartile 3. ^a Only among hospitalized patients.				

Table 1 Demographics, Prior Medication Use and Selected Outcomes Comparison Between Patients with COVID–19 with Rheumatoid Arthritis and Patients with COVID–19 without Rheumatoid Arthritis (cont.)

	Without RA (n = 137,757)	Without RA matched (n=3,042)	With RA (n = 1,035)	All COVID-19 (n = 138,792)
Steroids				
No	116,819 (84.8%)	2349 (77.2%)	497 (48.0%)	117,316 (84.5%)
Yes	20,938 (15.2%)	693 (22.8%)	538 (52.0%)	21,476 (15.5%)
Anti-coagulants				
No	134,593 (97.7%)	2888 (94.9%)	945 (91.3%)	135,538 (97.7%)
Yes	3,164 (2.3%)	154 (5.1%)	90 (8.7%)	3,254 (2.3%)
Any DMARD				
No	136286 (98.9%)	2985 (98.1%)	601 (58.1%)	136887 (98.6%)
Yes	1471 (1.1%)	57 (1.9%)	434 (41.9%)	1905 (1.4%)
csDMARD				
No	136,722 (99.2%)	2997 (98.5%)	699 (67.5%)	137,421 (99.0%)
Yes	1,035 (0.8%)	45 (1.5%)	336 (32.5%)	1,371 (1.0%)
tsDMARD				
No	137,705 (100.0%)	3042 (100%)	994 (96.0%)	138,699 (99.9%)
Yes	52 (0.0%)	0 (0%)	41 (4.0%)	93 (<0.1%)
bDMARD				
No	137,265 (99.6%)	3024 (99.4%)	844 (81.5%)	138,109 (99.5%)
Yes	492 (0.4%)	18 (0.6%)	191 (18.5%)	683 (0.5%)
Hospitalization				
No	116,322 (84.4%)	2342 (77.0%)	779 (75.3%)	117,101 (84.4%)
Yes	21,435 (15.6%)	700 (23.0%)	256 (24.7%)	21,691 (15.6%)
ICU^a				
No	17,861 (83.3%)	605 (81.2%)	210 (82.0%)	18,071 (83.3%)
Yes	3,574 (16.7%)	140 (18.8%)	46 (18.0%)	3,620 (16.7%)
Inpatient mortality^a				
No	18,949 (88.4%)	638 (85.6%)	218 (85.2%)	19,167 (88.4%)

Yes	2,486 (11.6%)	107 (14.4%)	38 (14.8%)	2,524 (11.6%)
Overall mortality				
No	134,249 (97.5%)	2,879 (94.6%)	970 (93.7%)	135,219 (97.4%)
Yes	3,508 (2.5%)	163 (5.4%)	65 (6.3%)	3,573 (2.6%)
bDMARD= biologics disease-modifying antirheumatic drugs; CCI= Charlson Comorbidity Index; COVID-19= Coronavirus disease 2019; csDMARD= conventional synthetic disease-modifying antirheumatic drugs; ICU= intensive care unit; RA= Rheumatoid Arthritis; SD= standard deviation; tsDMARD= targeted synthetic disease-modifying antirheumatic drugs; Q1= quartile 1; Q3= quartile 3. ^a Only among hospitalized patients.				

We matched 3,042 non-RA COVID-19 patients to 1,014 RA COVID-19 patients and 745 hospitalized non-RA COVID-19 patients to 249 hospitalized RA COVID-19 patients. All matching variables were well balanced post-match (Figure S1/S2). When comparing non-hospitalized patients with RA and matched patients without RA, we found no significant difference in the odds of hospitalization and mortality (hospitalization odds ratio [OR] 1.08, 95% confidence interval [CI]: [0.88,1.33]), mortality (OR 0.93, 95% [CI]: [0.65,1.34]). For matched hospitalized COVID-19 patients with RA (n=249) and patients without RA (n=745), we did not find significant differences in odds of transferring to ICU, or death during hospitalization (ICU: OR 0.94, 95% [CI]: [0.60,1.45], inpatient mortality: OR 0.86, 95% [CI]: [0.53,1.40]) (see [Table 2](#)). Treatments up to a year prior to the index date were also evaluated ([Table 3](#)). We found no significant effects except for anti-coagulants on the risk of hospitalization (OR 1.49, 95% [CI]: [1.10,2.02]) and overall mortality (OR 1.62, 95% [CI]: [1.04, 2.51]).

Our sensitivity analyses looking at laboratory-confirmed COVID-19 cases reduced our sample size by 32%. Results remained unchanged except that confidence intervals were wider (table S4-S6).

Table 2 Outcomes Among Patients with Rheumatoid Arthritis with COVID-19 and Matched Controls

a. Outcomes all COVID-19 patients					
	Matched Without RA (n=3042)	With RA (n=1014)	Overall (n=4056)	Crude OR (95% CI)	Adjusted OR ^a (95% CI)
Hospitalization					
No	2,342 (77.0%)	765 (75.4%)	3,107 (76.6%)	1.78 (1.55, 2.06)	1.08 (0.88, 1.33)
Yes	700 (23.0%)	249 (24.6%)	949 (23.4%)		
Mortality					
No	2,879 (94.6%)	953 (94.0%)	3,832 (94.5%)	2.56 (1.99, 3.30)	0.93 (0.65, 1.34)
Yes	163 (5.4%)	61 (6.0%)	224 (5.5%)		
b. Outcomes among hospitalized COVID-19 patients					
	Matched Without RA (n=745)	With RA (n=249)	Overall (n=994)	Crude OR (95% CI)	Adjusted OR ^a (95% CI)
ICU					
No	605 (81.2%)	204 (81.9%)	809 (81.4%)	1.09 (0.79 1.51)	0.94 (0.60, 1.45)
Yes	140 (18.8%)	45 (18.1%)	185 (18.6%)		
Inpatient					

mortality					
No	638 (85.6%)	213 (85.5%)	851 (85.6%)	1.33 (0.94, 1.88)	0.86 (0.53, 1.40)
Yes	107 (14.4%)	36 (14.5%)	143 (14.4%)		

CI = confidence interval; OR=odds ratio; RA=Rheumatoid Arthritis.
^a Results are based on multiple logistic regression adjusting for age, race/ethnicity, sex, body mass index (BMI), comorbidities, and pre-index medication such as steroids, anti-coagulants, antibiotics, csDMARD and bDMARD.

Table 3 The effects of treatment on different outcomes evaluated

Treatment	Outcomes among all COVID-19 patients		Outcomes among all Hospitalized COVID-19 patients	
	OR (95% CI)		OR (95% CI)	
	Hospitalization	OS	ICU	Inpatient mortality
Steroids	0.83 (0.68, 1.01)	0.99 (0.70, 1.40)	0.93 (0.60, 1.44)	0.85 (0.53, 1.37)
Anti-coagulants	1.49 (1.10, 2.02)	1.62 (1.04, 2.51)	1.68 (0.97, 2.94)	1.44 (0.78, 2.68)
csDMARD	0.76 (0.55, 1.04)	0.66 (0.36, 1.22)	0.73 (0.35, 1.52)	0.76 (0.33, 1.76)
bDMARD	0.69 (0.45, 1.05)	1.19 (0.58, 2.42)	1.87 (0.78, 4.49)	2.42 (0.93, 6.29)

CI = confidence interval; OR = odds ratio; RA = Rheumatoid Arthritis; OS = overall survival. Results are based on multiple logistic regression adjusting for sex, age, race/ethnicity, body mass index (BMI), and comorbidities.

Discussion

It has been hypothesized that persons using immunosuppressive medications might be at higher risk of severe COVID-19 outcomes due to a compromised immune system and inability to suppress early viral replication. However, we did not find evidence to suggest patients with COVID-19 and RA are more likely to have severe outcomes after matching. We also did not find any effect of pre-COVID-19 DMARD treatments on the risk of COVID-19 related outcomes.

There is a growing body of conflicting literature examining COVID-19 outcomes among RA patients. While some studies reported increased risk of hospitalization¹⁵ and death¹⁶ among combined populations of patients with inflammatory conditions, specific analyses focusing on RA populations have suggested that there is no increased risk of hospitalization.^{7 17} However, when examining RA treatments, some studies suggest a possible protective effect of b/tsDMARDs⁷ and anti-TNF therapy^{7 15} on risk of hospitalization, while increased risk of hospitalization was reported for JAK inhibitor users¹⁵. Directionally, findings from our paper also suggested similar results, with a non-statistically significant reduced risk of hospitalization among bDMARD users. Subsequent analysis of the hospitalized patients showed non-statistically significant elevated risks of ICU stay and mortality. Notably, in our sensitivity analyses using only lab confirmed COVID-19 cases, the directional association showing reduced risk of hospitalization remained for all COVID-19 patients, while among hospitalized patients, the risk of ICU and mortality was no longer elevated.

When characterizing patients with and without severe outcomes, we found older age, male gender, smokers, and higher CCI are associated with severe outcomes (online supplemental table S7-S8). Patients utilizing anti-coagulants in the pre-COVID-19 period had significantly increased risk of hospitalization and mortality (Table 3). Similar, non-significant results were found among hospitalized patients (online supplemental table S9-S10). The effect of anti-coagulant use was the same across populations with or without RA.

COVID-19 is known to be associated with abnormal coagulation, specifically higher clot formation¹² and subsequent increased risk of mortality.^{13 14} Patients using anti-coagulants may have comorbidities that predispose them to worse outcomes from COVID-19 (cardiovascular disease, malignancy, or another hypercoagulable state) despite the potential protective effect of the anti-coagulant itself. Alternatively, the anti-coagulants themselves could paradoxically be causing worse COVID-19 outcomes, perhaps by increasing the risk of bleeding complications. Distinguishing between these hypotheses could have important implications for the treatment of patients with COVID-19; however, further study is required.

Although the scope of this study is limited to information captured by participating HCOs and might not be reflective of patients' complete medical encounters, medication use and detailed disease conditions such as disease activities, this is the largest published study examining the risk of severe outcomes among patients with COVID-19 and RA to date. Worse COVID-19 outcomes were not seen among patients with RA, regardless of historical RA therapy. These findings suggest that asymptomatic patients with RA should stay on their routine RA therapy, though it is still unclear whether or not RA or other medications should be discontinued after COVID-19 infection.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*2020;20:533–34 [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
2. Incerti D, Rizzo S, Li X, et al. Risk factors for mortality among hospitalized patients with COVID-19 *medRxiv*Published Online First: 2 October 2020. <https://doi.org/10.1101/2020.09.22.20196204>
3. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people?. *Aging (Albany NY)*2020;10:9959–81 <https://doi.org/10.18632/aging.103344>.
4. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. *SN Compr Clin Med*2020;1–8 <https://doi.org/10.1007/s42399-020-00363-4>.
5. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Ann Intern Med*2020;173:773-81 <https://doi.org/10.7326/M20-3742>.
6. Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the united states during early days of the COVID-19 pandemic. *ACR Open Rheumatol* 2020;2:335–43 <https://doi.org/10.1002/acr2.11148>.
7. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis*2020;79:859–66 <https://doi.org/10.1136/annrheumdis-2020-217871>.
8. Richez C, Flipo R, Berenbaum F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: the french society of rheumatology answers to most frequently asked questions up to may 2020 *Joint Bone Spine*2020;87:431–37 <https://doi.org/10.1016/j.jbspin.2020.05.006>.
9. Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. *Rheumatol Int*2020;40:825–26 <https://doi.org/10.1007/s00296-020-04570-z>.
10. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis*2020;79:667–68 <https://doi.org/10.1136/annrheumdis-2020-217424>.
11. Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?. *Arthritis Rheumatol*2020;72:1600–06 <https://doi.org/10.1002/art.41388>.
12. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res*2020;220:1–13 <https://doi.org/10.1016/j.trsl.2020.04.007>.

13. Connors JM., Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*2020;135:2033–40 <https://doi.org/10.1182/blood.2020006000>.
14. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*2020;136:489–500 <https://doi.org/10.1182/blood.2020006520>.
15. Haberman, Rebecca H., Rochelle Castillo, Alan Chen, Di Yan, Deborah Ramirez, Vaish Sekar, Robert Lesser, et al. n.d. “COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes.” *Arthritis & Rheumatology* n/a (n/a). Accessed August 14, 2020. <https://doi.org/10.1002/art.41456>.
16. Williamson, Elizabeth J., Alex J. Walker, Krishnan Bhaskaran, Seb Bacon, Chris Bates, Caroline E. Morton, Helen J. Curtis, et al. 2020. “Factors Associated with COVID-19-Related Death Using OpenSAFELY.” *Nature* 584 (7821): 430–36. <https://doi.org/10.1038/s41586-020-2521-4>.
17. Hyrich, Kimme L., and Pedro M. Machado. 2020. “Rheumatic Disease and COVID-19: Epidemiology and Outcomes.” *Nature Reviews. Rheumatology*, December, 1–2. <https://doi.org/10.1038/s41584-020-00562-2>.